LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis

Lili Zhou 1*, Xiao Jia 2 and Xiangzheng Yang 1

Abstract

**Background:** Previous studies indicated that lncRNA taurine upregulated gene 1 (TUG1) played essential roles in human cancers. This study aimed to investigate its function in infantile hemangioma (IH).

**Methods:** A total of 30 pairs of clinical infantile specimens were used in this study. The expression of TUG1 in IH tissues was assessed by quantitative reverse transcriptase PCR (qRT-PCR). Two short hairpin RNA targeting TUG1 (sh-TUG1-1 and sh-TUG1-2) were transfected into hemangioma-derived endothelial cells, HemECs, to block its expression. The effects of TUG1 on HemECs were evaluated by Cell Counting Kit-8 (CCK-8), colony formation assay, wound healing assay, and Transwell assay. The underlying molecular mechanism of TUG1 was investigated by Starbase prediction and luciferase reporter assay and further determined by loss- and gain-of-function approaches. In addition, the role of TUG1 on tumorigenesis of HemECs was confirmed in an in vivo mouse model.

**Results:** TUG1 was significantly upregulated in infant hemangioma tissues compared with normal adjacent subcutaneous tissues. The loss- and gain-of-function approaches indicated that TUG1 overexpression promoted proliferation, migration, and invasion of HemECs in vitro, and TUG1 knockdown inhibited the tumorigenesis of HemECs in vivo. Specifically, TUG1 could compete with IGFBP5 for miR137 binding. Rescue experiments further confirmed the role of the TUG1/miR137/IGFBP5 axis in HemECs.

**Conclusion:** TUG1 was closely associated with the progression of IH by regulating the miR-137/IGFBP5 axis, which might be a potential target for IH treatment.

**Keywords:** Infantile hemangioma, TUG1, miR137, IGFBP5, Tumorigenesis

Background

Infantile hemangioma (IH) is one of the common malignancies, leading to higher mortality in the infant population [1]. Previous reports suggest that IH occurs in up to 10% of non-Hispanic Caucasian infants and is more prevalent in premature, low birth weight, and multiple-birth babies [2, 3]. Although several key genes have been revealed to be involved in IH development [4, 5], the mechanisms underlying IH progression are still not completely known.

Long noncoding RNAs (lncRNAs) are a widely known class of noncoding RNAs with more than 200 nucleotides in length and often regulate the expression of downstream genes at the post-transcriptional level [6]. Increasing evidence indicates that lncRNAs possess various regulatory functions in cancer progression, including proliferation, migration, and invasion [7]. lncRNA taurine upregulated gene 1 (TUG1) is one of the first identified lncRNAs associated with human diseases [8]. For example, TUG1 promotes cell proliferation and inhibits
apoptosis by targeting AURKA in epithelial ovarian cancer [9]. TUG1 promotes proliferation, migration, and epithelial-mesenchymal transition of papillary thyroid cancer cells by targeting miR-145 [10]. TUG1 promotes the progression of osteosarcoma through modulating RUNX2 expression [11]. In addition, TUG1 is also associated with the development of breast cancer [12], colorectal cancer [13], and gastric cancer [14]. These reports confirmed the crucial roles of TUG1 in human cancers. However, the function of TUG1 in IH remains unclear.

MicroRNAs (miRNAs) are also noncoding RNAs with approximately 22 nucleotides in length and can bind to the 3’ UTR of their target genes to inhibit their translation [15]. Many studies have demonstrated that miRNAs affect the progression of IH and may be considered as potential biomarkers. Downregulation of miR-382 inhibits IH progression by regulating the PTEN-mediated AKT/mTOR signaling pathway [16]. MiR-143 acts as a suppressor of IH by targeting Bcl-2 [16]. MiR-137 is a rarely reported microRNA that has been only studied in melanoma. Qi et al. found that miR-137 is downregulated in melanoma cell lines and tissues, and knockdown of miR-137 inhibits melanoma cell invasion and migration [17]. In addition, one recent study demonstrated that miR-137 was a target of TUG1, and this axis closely participated in the migration and invasion of hepatocellular carcinoma cells [18]. Insulin-like growth factor-binding protein 5 (IGFBP5), a member of the insulin superfamily of growth-promoting peptides, has been revealed to be the most abundant polypeptide growth factor [19]. Its role in tumors has been extensively studied. Some showed that IGFBP5 played a negative role in tumor progression by suppressing tumor cell proliferation and metastasis [20, 21]. Rho et al. showed that IGFBP5 expression prevented tumor growth and inhibited tumor vascularity in a xenograft model of human ovarian cancer [20]. Butt et al. showed that IGFBP5 promoted breast cancer cell apoptosis via Bcl-2 in the intrinsic apoptotic pathway [22]. However, other studies showed that IGFBP5 played a positive role in tumor progression by promoting tumor cell survival and migration [23–25]. In addition, IGFBP5 acts as an oncogene in different cancers such as gastric cancer [26], colorectal cancer [27], prostate cancer [28], glioblastoma [29], human melanoma [30], and breast cancer [23]. To date, it is not clear that the role and exact mechanisms of IGFBP5 in IH progression. Previous studies reported that miR-137 suppressed cell proliferation and migration of vascular smooth muscle cells by targeting IGFBP-5 [31], suggesting that IGFBP5 was a target of miR-137.

In the present study, we found that TUG1 was significantly upregulated in infant hemangioma tissues, especially in proliferating-phase hemangioma tissues. Knockdown of TUG1 efficiently inhibited proliferation, migration, and invasion of HemECs in vitro and obviously reduced tumorigenesis of HemECs in vivo. Moreover, TUG1 was found to regulate IGFBP5 expression by directly sponging miR-137, and the miR-137/IGFBP5 axis mediated the roles of TUG1 in IH progression.

**Methods**

**Clinical specimens**

A total of 30 pairs of clinical infantile specimens, including hemangioma tissues and normal adjacent subcutaneous tissues surrounding hemangiomas, were collected from 30 infantile hemangioma patients at Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) from 2015 to 2019. The specimens were immediately frozen at −80 °C or in liquid nitrogen until further analysis. Among them, 15 were from patients with proliferative hemangiomas (13 females and 2 males; average age 6 months) and 15 from patients with involuting hemangiomas (10 females and 5 males; average age 7 months). The parents/legal guardians of all participants have signed the informed consent. This study was approved by the Human Ethics Committee of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) and conducted in accordance with the guidelines of the Declaration of Helsinki.

**Cell isolation and culture**

Hemangioma-derived endothelial cells, HemECs, were isolated from infant hemangioma tissues at the proliferating phase as previously described [32]. HEK-293T cells (Life Technologies) were used for luciferase reporter assay. HemECs and HEK-293T cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) with 5% CO₂ at 37 °C.

**Cell transfection**

Two short hairpin RNA targeting TUG1, sh-TUG1-1 (5’-GACTACCTTCCCTGTCATT-3’) and sh-TUG1-2 (5’-TGCAACTGACATGCTAGCGA-3’) and the non-targeting sh-RNA (sh-NC) were obtained from GenePharma (Shanghai, China). To overexpress TUG1 and IGFBP5, the full lengths of TUG1 and IGFBP5 were synthesized from GenePharma (Shanghai, China) and cloned into the pcDNA3.1 vector (GenePharma, Shanghai, China) to generate TUG1 and IGFBP5 overexpressing vector, respectively. The empty vector pcDNA3.1 was used as the negative control. MiR-137 mimics, NC mimics, miR-137 inhibitor, and NC inhibitor were purchased from GenePharma (Shanghai, China), and their sequences are shown in Table 1. Cell transfection was performed using Lipofectamine 3000 (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol.
Cell proliferation
Approximately $1 \times 10^4$ HemECs with 48 h of transfection were seeded each well of 96-well plates. At 24, 48, 72, and 96 h after inoculation, 10 μl of Cell Counting Kit-8 (CCK-8) solution (Dojindo Molecular Technologies, Inc.) was added into each well, and the plates were incubated for 2 h. After that, cell viability was determined by measuring the absorbance at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).

Colony formation assay
Cell proliferation was also evaluated by colony formation assay. In brief, approximately 1000 HemECs were seeded into 6-well plates and cultured for 14 days. Cells were fixed in formalin and stained with 0.1% crystal violet (Solarbio), and then the colonies were photographed and counted under a digital camera.

Migration assay
Approximately $1 \times 10^4$ transfected or un-transfected HemECs/well were seeded into 6-well plates and cultured for 24 h. The cell monolayers were scratched using a 100-μl micropipette tip. After the floating cells and debris cells were washed out with PBS, cell migration was observed and photographed under a light microscope (Olympus, Tokyo, Japan) at 0 h and 48 h.

Invasion assay
Cell invasion was evaluated by using the 8-mm pore-size Transwell filters (Costar, Corning Incorporated) as previously described [33]. Briefly, $1 \times 10^4$ HemECs/well in 100 μL of FBS-free DMEM were placed on the upper chambers of the Transwell in a 24-well plate, and the lower chambers were filled with 300 μL of DMEM with 10% FBS. After 24 h of incubation, the cells invaded the lower surface of the filter were stained using crystal violet staining, counted, and photographed using a light microscope (Olympus, Tokyo, Japan).

Quantitative real-time PCR (qRT-PCR)
Total RNA of tissues and cultured cells was extracted using Trizol (Thermo Fisher Scientific). About 1 μg of RNA was reverse transcribed into cDNA using the Reverse Transcription Kit (Takara, Dalian, China). The fold expression change of target genes was analyzed on an ABI 7500 PCR system (Applied Biosystems) using the Power SYBR™ Green PCR master mix (Thermo Fisher Scientific, Inc.). U6 and GAPDH were used as the internal control for miR-137 and TUG1/IGFBP5, respectively. Data were calculated using the $2^{-\Delta\Delta Ct}$ method. The primer sequences are shown in Table 2.

Western blot
Total protein samples of tissues and cultured cells were extracted using RIPA lysis buffer (Beyotime Institute of Biotechnology). Approximately 10 μg protein samples were separated on 12% SDS-PAGE and transferred onto PVDF membranes. After blocked with 5% skimmed milk, the membranes were incubated with primary antibodies against IGFBP5 (Abcam, ab254324. 1:500), Ki67 (Abcam, ab15580. 1:500), and GAPDH (Abcam, ab9485, 1:1000) overnight at 4 °C. On the following day, the membranes were exposed to horseradish peroxidase-conjugated secondary antibody for 2 h. The signals were detected using an enhanced chemiluminescence detection kit (ECL, Bio-Rad, Hercules, CA, USA).

Luciferase reporter assay
The putative binding sites between TUG1 and miR-137 and between miR-137 and IGFBP5 were predicted by Starbase. The fragments of TUG1 and IGFBP5 containing the wild type (WT) or mutant type (MUT) miR-137 binding site were obtained from GenePharma (Shanghai, China) and inserted into pmirGLO luciferase vector (GeneCreat, China) to generate the recombinant vector TUG1/IGFBP5 3′-UTR WT/MUT. HEK-293T cells were co-transfected with the recombinant vectors and miR-137 mimics or NC mimics using Lipofectamine 3000. At 48 h of transfection, the relative luciferase reporter activity was detected using the dual luciferase reporter system (Promega).

In situ hybridization (ISH)
The hemangioma tissue and adjacent normal tissues were fixed in 4% formalin, embedded in paraffin, and cut into 5-μm sections. The Digoxin-labeled ISH probe for TUG1 was synthesized by GenePharma (Shanghai, China) and inserted into pmirGLO luciferase vector (GeneCreat, China) to generate the recombinant vector TUG1/IGFBP5 3′-UTR WT/MUT. HEK-293T cells were co-transfected with the recombinant vectors and miR-137 mimics or NC mimics using Lipofectamine 3000. At 48 h of transfection, the relative luciferase reporter activity was detected using the dual luciferase reporter system (Promega).

Table 1 The sequences of mimics and inhibitor

| Sense | Antisense |
|-------|-----------|
| MiR-137 mimics | 5′-UUAUUGCUUAGAAUACGGUAG-3′ |
| NC mimics | 5′-UUGCCGAAGGGUUCACGUTT-3′ |
| miR-137 inhibitor | 5′-CUACGCGUAUUCUUAAGCAUUAA-3′ |
| NC inhibitor | 5′-CAGUACUUUGUUGUAGUACAA-3′ |
photographed using a Zeiss invert microscope (Carl- Zeiss, Hallbergnoos, Germany).

Immunofluorescence
IGFBP5 expression in HemECs was evaluated by immunofluorescence using an anti-IGFBP5 antibody. In brief, transfected or un-transfected HemECs were permeabilized in 0.1% Triton X-100 and incubated with anti-IGFBP5 primary antibody (Abcam, ab254324, 1:500) overnight at 4 °C. Cells were then incubated with FITC-conjugated goat anti-rabbit secondary antibody (Abcam, ab15580, 1:500) at 4 °C overnight, followed by 2 h incubation with the secondary antibody working solution (Dako, GK500705). Subsequently, Ki-67 expression in tumor tissues was observed using a DAB Substrate Kit (Invitrogen, USA) according to the manufacturer’s protocol.

In vivo model
BALB/c nude mice (male, 5-week-old) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. Then, 100 μl PBS containing 5 × 10⁶ sh-TUG1-1 or sh-NC transfected HemECs cells were subcutaneously inoculated into BALB/c nude mice as previously described [34] with five mice in each group. Tumor volume was evaluated every week for a total of 5 weeks based on the formula: length × width²/2. On day 35, mice were sacrificed by cervical dislocation, and the tumors were collected and weighted. All animal experiments were approved by the Animal Ethics Committee of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang).

Immunohistochemistry (IHC) assay
The tumors from the in vivo model were fixed in 4% formalin, embedded in paraffin, and cut into 3-μm sections. The sections were incubated with anti-Ki67 antibody (Abcam, ab15580, 1:500) at 4 °C overnight, followed by 2 h incubation with the secondary antibody working solution (Dako, GK500705). Subsequently, Ki-67 expression in tumor tissues was observed using a DAB Substrate Kit (Invitrogen, USA) according to the manufacturer’s protocol.

Statistical analysis
Data were presented as mean ± standard deviation (SD) and statistically analyzed using SPSS 19.0 (IBM Corp.). Spearman’s correlation analysis was used to evaluate the relationship between the level of TUG1 and miR-137, as well as miR-137 and IGFBP5 in infant hemangioma tissues. Differences between two groups were tested by Student’s t test, and differences among multiple groups were determined by one-way ANOVA followed by Tukey’s multiple comparisons test. A p < 0.05 was considered a significant threshold, and a p < 0.01 was considered an extremely significant threshold.

Results
TUG1 was highly expressed in IH tissues
To explore the role of TUG1 in IH progression, we firstly detected TUG1 expression in IH tissues and found that TUG1 was significantly upregulated in IH tissues compared with the adjacent normal subcutaneous tissues (p < 0.01 for proliferating-phase hemangioma tissues and p < 0.01 for involuting-phase hemangioma tissues). In addition, TUG1 expression was significantly higher in the proliferating-phase hemangioma tissues than in the involuting-phase hemangioma tissues (p < 0.01) (Fig. 1A). Meanwhile, TUG1 expression in IH tissues was also evaluated by ISH assay. The results showed that TUG1 was upregulated in IH tissues, especially in the proliferative-phase hemangioma tissues (Fig. 1B). These results indicate that TUG1 may play a potential oncogenic role in IH progression.

TUG1 knockdown inhibited HemEC proliferation, migration, and invasion in vitro
To determine the oncogenic role of TUG1 in IH, two sh-RNAs targeting TUG1 were transfected into HemECs. qRT-PCR confirmed that sh-TUG1-1 exhibited the best silencing effect (p < 0.01, Fig. 2A). As shown in Fig. 2B and C, both sh-TUG1-1 and sh-TUG1-2 efficiently reduced the proliferation of HemECs compared with the negative control sh-NC (sh-TUG1-1: p < 0.05 at 48 h, p < 0.01 at 72 h, p < 0.01 at 96 h; sh-TUG1-2: p < 0.05 at 48 h, p < 0.05 at 72 h, p < 0.01 at 96 h, Fig. 2B; both p < 0.01, Fig. 2C). The wound healing assay results showed that both sh-TUG1-1 and sh-TUG1-2 significantly inhibited the migration ability of HemECs compared with sh-NC (both p < 0.01, Fig. 2D). In addition, both sh-TUG1-1 and sh-TUG1-2 significantly inhibited the invasion capacity of HemECs compared

Table 2 The sequences of primers

|         | Forward       | Reverse       |
|---------|---------------|---------------|
| TUG1    | 5′-CTGAAAGAAAGGCAACATC-3′ | 5′-GTAGGCTACTACAGGATTGTG-3′ |
| miR-137 | 5′-CGGCGTTATGCTTAAGAATA-3′ | 5′-GCAAGGTCGGAGATTTC-3′ |
| U6      | 5′-CTCGCTTCCCGACACA-3′ | 5′-AACGCTTCAGAAATTGGTG-3′ |
| IGFBP5  | 5′-GCACCTGAGATGAGACAGGA-3′ | 5′-TGTAGAATCTTTTCGGTCA-3′ |
| GAPDH   | 5′-CGGAACCAATACGACCAATCCG-3′ | 5′-AGCCACATCGCTACAGACACC-3′ |
with sh-NC (both $p < 0.01$, Fig. 2E). These observations suggested that TUG1 knockdown inhibited the proliferation, migration, and invasion of HemECs in vitro.

**TUG1 acted as a sponge of miR-137**

To explore the mechanism of TUG1, Starbase (http://starbase.sysu.edu.cn/index.php) was used, and the prediction suggested that miR-137 might bind to the 3′-UTR of TUG1 (Fig. 3A). A luciferase reporter assay was performed to determine their interaction, and the results indicated that miR-137 overexpression significantly reduced the relative luciferase activity of TUG1 3′-UTR WT compared with NC mimics ($p < 0.01$) but did not alter the luciferase activity of TUG1 3′-UTR MUT (Fig. 3B). Meanwhile, TUG1 knockdown in HemECs by transfection of sh-TUG1-1/2 significantly increased miR-137 expression compared with sh-NC (both $p < 0.01$, Fig. 3C). Next, miR-137 mimics/inhibitor and corresponding negative controls were transfected into HemECs, and the transfection efficiencies were confirmed by qRT-PCR ($p < 0.01$, miR-137 mimics vs. NC mimics; $p < 0.01$, miR137 inhibitor vs. NC inhibitor; Fig. 3D). The results of qRT-PCR showed that the transfection of miR-137 mimics significantly reduced TUG1 expression compared with NC mimics ($p < 0.01$), and the transfection of miR-137-inhibitor significantly increased TUG1 expression compared with NC inhibitor ($p < 0.01$, Fig. 3E). Moreover, miR-137 expression was markedly downregulated in infant hemangioma tissues than in adjacent normal subcutaneous tissues ($p < 0.01$, Fig. 3F). Spearman’s correlation analysis indicated that TUG1 levels were negatively correlated to miR-137 levels in infant hemangioma tissues ($p < 0.05$, $R^2 = 0.1806$, Fig. 3G). These results indicated that TUG1 served as a sponge of miR-137 in IH.

**MiR-137 inhibited HemEC proliferation, migration, and invasion by regulating IGFBP5**

To further investigate the mechanism underlying the roles of TUG1 in IH, HemECs were transfected with miR-137 mimics and NC mimics, and HemEC proliferation was evaluated by CCK-8 assay (Fig. 4A) and colony formation assay (Fig. 4B). The results showed that miR137 overexpression significantly inhibited HemEC
proliferation compared with NC mimics ($p < 0.05$ at 48 h, $p < 0.01$ at 72 h, $p < 0.01$ at 96 h, Fig. 4A; $p < 0.01$, Fig. 4B). Moreover, wound healing assay and Transwell assay showed that miR-137 overexpression significantly inhibited the migration and invasion of HemECs compared with NC mimics (both $p < 0.01$, Fig. 4C and D). The prediction using Starbase showed that there was a putative binding site between miR-137 and IGFBP5 (Fig. 4E), suggesting that IGFBP5 might be a target of miR-137. Luciferase reporter assay in HEK-293T cells indicated that transfection of miR-137 mimics significantly reduced the relative activity of IGFBP5 3′-UTR WT ($p < 0.01$), but not IGFBP5 3′-UTR MUT, compared with NC mimics (Fig. 4F). HemECs were transfected with the overexpressing vector for TUG1 (TUG1), and the transfection efficiency was confirmed by qRT-PCR ($p < 0.01$, Fig. 4G). The rescue experiment results showed that overexpression of miR-137 mimics reduced IGFBP5 expression compared with NC mimics ($p < 0.01$), and co-transfection of miR-137 mimics and TUG1 obviously reversed the inhibitory effect of miR-137 mimics ($p < 0.01$, Fig. 4H and I). In addition, IGFBP5 expression in HemECs was also evaluated by immunofluorescence using an anti-IGFBP5 antibody, and the results showed that the transfection of miR-137 mimics obviously reduced IGFBP5 expression, and co-transfection of miR-137 mimics and TUG1 reversed the inhibitory effect of miR-137 mimics (Fig. 4J). These results suggested that miR-137 inhibited the proliferation, migration, and invasion of HemECs via regulating IGFBP5.

**MiR-137 mediated the role of TUG1 in HemECs**

Subsequently, we explored whether miR-137 mediated the role of TUG1 in IH and transfected miR-137 mimics or co-transfected with miR-137 mimics and TUG1 into HemECs. QRT-PCR indicated that transfection of miR-137 mimics significantly reduced TUG1 expression compared with NC mimics ($p < 0.01$), and co-transfection of miR-137 mimics and TUG1 rescued TUG1 expression ($p < 0.01$, Fig. 5A). As shown in Fig. 5B–E, transfection of miR-137 mimics significantly inhibited the proliferation, migration, and invasion of HemECs compared with
NC mimics, and co-transfection of miR-137 mimics and TUG1 obviously reversed the inhibitory effect of miR-137 mimics. These results indicated that the role of TUG1 in IH might be partially mediated by miR-137.

**TUG1 knockdown inhibited HemEC proliferation, migration, and invasion by regulating IGFBP5**

To investigate whether TUG1 regulated the progression of HemECs by modulating IGFBP5, HemECs were transfected with IGFBP5 and the empty vector pcDNA3.1, and the transfection efficiency was confirmed by qRT-PCR ($p < 0.01$, Fig. 6A) and Western blot (Fig. 6B). In addition, sh-TUG1-1 transfection significantly reduced IGFBP5 expression compared with sh-NC in HemECs ($p < 0.01$), and co-transfection of sh-TUG1-1 and IGFBP5 obviously rescued the induction effects of sh-TUG1-1 on IGFBP5 expression ($p < 0.01$, Fig. 6C and D). Moreover, co-transfection of sh-TUG1-1 and IGFBP5 significantly reversed the inhibitory effects of sh-TUG1-1 on proliferation, migration, and invasion of HemECs (Fig. 6E–H). These results indicated that TUG1 knockdown inhibited the proliferation, migration, and invasion of HemECs by downregulating IGFBP5.
TUG1 knockdown inhibited the tumorigenesis of HemECs in vivo

To confirm the oncogenic role of TUG1 in IH progression, an in vivo animal model was established by subcutaneously inoculating sh-TUG1-1-transfected HemECs. TUG1 expression in tumor tissues was evaluated by qRT-PCR, and the results showed that TUG1 level was lower in tumor tissues of the sh-TUG1-1 group than that of sh-NC group ($p < 0.01$, Fig. 7A). As shown in Fig. 7B–D, sh-TUG1-1 obviously reduced tumor volume and tumor weight of mice compared with sh-NC ($p < 0.03$ at day 3, $p < 0.01$ at day 4, $p < 0.01$ at day 5, Fig. 7C; $p < 0.01$, Fig. 7D). Meanwhile, the number of Ki-67 positive cells was significantly reduced in tumor tissues of sh-TUG1-1 group compared with that of sh-NC group ($p < 0.01$, Fig. 7E). In addition, miR-137 expression was significantly increased, and IGFBP5 expression was reduced in tumor tissues of sh-TUG1-1 group compared with that of sh-NC group ($p < 0.01$ for miR137, $p < 0.01$ for IGFBP5, Fig. 7F). IGFBP5 and Ki-67 levels in tumor tissues were confirmed by Western blot (Fig. 7G). These results suggested that TUG1 knockdown inhibited the tumorigenesis of HemECs in vivo by regulating miR-137 and IGFBP5.

**Discussion**

As the most common vascular tumors of infancy, IH has become a threat to vision and even life depending on the location and size of the lesion [35] and drawn more attention to develop efficient therapeutic strategies, which
may depend on the well understanding of IH pathogenesis [36]. In the present study, we provided that lncRNA TUG1 might be a novel target for IH treatment and extended the mechanism by which TUG1 affected IH progression by regulating the miR-137/IGFBP5 axis.

Increasing evidences demonstrate the essential roles of lncRNAs in IH progression. For example, MALAT1 is highly expressed in IH tissues, and MALAT1 knockdown inhibits HemEC proliferation, apoptosis, migration, invasion, and tube formation rate [34]. NEAT1 silencing inhibits IH tumorigenesis by competitively sponging miR-33a-5p to activate HIF1alpha/NF-kB signaling pathway [37]. Linc00152 knockdown exerts a potent anti-hemangioma effect by inactivating the Akt/mTOR pathways [38]. However, the effects of more lncRNAs in IH needed to be further explored. Although lncRNA TUG1 has been well studied in many human cancers [39], its role in IH progression has not been explored. In this study, we found that TUG1 was a potential oncogene, and TUG1 knockdown efficiently inhibited HemEC progression both in vitro and in vivo. Interestingly, we found the oncogenic role of TUG1 in IH, suggesting that it might act as a potential therapeutic target for IH.

We identified that TUG1 acted as the sponge of miR-137 and confirmed their relationship using the luciferase reporter assay. Previous studies reported that several miRNAs are direct targets of TUG1 except for miR-137 and mediate the role of TUG1 in human diseases. TUG1 has been identified to sponger miR-145a-5p to affect microglial polarization after oxygen-glucose deprivation [40]. TUG1 alleviates sepsis-induced acute lung injury

Fig. 5 MiR-137 mediated the role of TUG1 in HemECs. HemECs were transfected with miR-137 mimics, NC mimics, or co-transfected with miR-137 mimics and TUG1 (the overexpressing vector for TUG1). A TUG1 expression was assessed by qRT-PCR. B, C Cell proliferation was evaluated by CCK-8 assay (B) and colony formation assay (C). D Cell migration was evaluated by the wound healing assay. E Cell invasion was evaluated by Transwell assay. Data were derived from three independent experiments and expressed as mean ± SD. * P < 0.05, ** P < 0.01
by targeting miR-34b-5p/GAB1 [41]. In addition, there are some other miRNAs such as miR-148b in ox-LDL-stimulated vascular smooth muscle cells and umbilical vein endothelial cells [42] and miR-145 in papillary thyroid cancer [10]. Function assays revealed that miR-137 overexpression obviously reversed the inhibitory effects of TUG1 knockdown on HemEC proliferation, migration, and invasion. However, the correlation between TUG1 and miR-137 and its role in IH progression have not been reported. Our study revealed that miR-137 was also a target of TUG1 and participated in the function of TUG1 in the tumorigenesis of HemECs. Our study provided a new function of miR-137 in IH progression.

More and more reports have indicated that miRNAs participate in cancer progression mainly via inhibiting the translation of key genes involved in cellular metabolism and phenotypic transition [43]. Their roles in IH have also been widely reported. For example, miR-424 inhibits the proliferation of hemangioma-derived endothelial cells by targeting VEGFR-2 [44]. MiR-424 suppresses cell proliferation, migration, and tube formation capabilities in IH via bFGF/FGFR1 pathway [4]. miR-130a silencing inhibits IH progression by modulating targeting tissue factor pathway inhibitor 2-mediated FAK signaling pathway [45]. We found that IGFBP5 was a target of miR-137 and IGFBP5 overexpression significantly reversed the inhibitory effects of miR-137 mimics and TUG1 knockdown on HemEC proliferation, migration, and invasion. Although IGFBP5 was found to act as a key risk factor in various human diseases in previous studies [26, 46], its role in IH remains unclear. Our study revealed that TUG1 and miR137 participated in IH progression through regulating IGFBP5 expression both in vitro and in vivo and provided that IGFBP5

Fig. 6 TUG1 knockdown inhibited HemEC proliferation, migration, and invasion via regulating IGFBP5. A, B HemECs were transfected with IGFBP5 (the overexpressing vector for IGFBP5) or the empty vector pcDNA3.1. The transfection efficiency was confirmed by qRT-PCR (A) and Western blot (B). C–H HemECs were transfected with sh-TUG1-1, sh-NC, or co-transfected with sh-TUG1-1 and the empty vector pcDNA3.1, or sh-TUG1-1 and IGFBP5 (the overexpressing vector for IGFBP5). IGFBP5 expression was evaluated by qRT-PCR (C) and Western blot (D). Cell proliferation was evaluated by CCK-8 assay (E) and colony formation assay (F). G Cell migration was evaluated by the wound healing assay. H Cell invasion was evaluated by Transwell assay. Data were derived from three independent experiments and expressed as mean ± SD. * P < 0.05, ** P < 0.01
functioned as a risk gene in IH. Moreover, an in vivo mouse model was used to confirm the potential oncogenic role in IH. However, the signaling pathway(s) involved in the roles of the TUG1/miR-137/IGFBP5 axis in IH need to be further investigated in subsequent experiments.

Our results showed that LncRNA as a sponge by competing for miR-137 binding to regulate the IGFBP5 expression, thereby promoting IH progression. Yang et al. showed that LncRNA MIR31HG is a miR-193b sponge and miR-193b overexpression suppresses MIR31HG expression and function, suggesting that MIR31HG is a target of miR-193b [47]. Interestingly, we also found that miR-137 overexpression suppresses LncRNA TUG1 expression and function, suggesting that LncRNA TUG1 may be a target of miR-137, which needs to be further investigated in subsequent experiments. In addition, we found that TUG1 knockdown inhibited the tumorigenesis of HemECs in vivo, accompanied by miR-137 upregulation and IGFBP5 downregulation in tumor tissues. These results suggested that LncRNA TUG1 depletion suppressed the tumorigenesis of IH by reducing competitively binding of miR-137 to inhibit IGFBP5 expression. Therefore, blocking the TUG1/miR-137/IGFBP5 signaling pathway may represent a potential antitumor therapeutic strategy.
Conclusions
Our study demonstrated that TUG1 functioned as onco-
genic lncRNA in IH by sponging miR-137 to upregulate
IGFBP5, providing a novel insight for IH pathogenesis.

Abbreviations
IH: Infantile hemangioma; qRT-PCR: Quantitative reverse transcriptase PCR;
CCK-8: Cell Counting Kit-8; lncRNAs: Long noncoding RNAs;
microRNAs: MicroRNAs; sh-TUG: Short hairpin RNA targeting TUG;
IGFBP5: Insulin-like growth factor-binding protein 5; ISH: In situ hybridization;
IHC: Immunohistochemistry; TUG1: Taurine upregulated gene 1

Acknowledgements
Not applicable.

Authors’ contributions
LLJ: manuscript writing, experimental work, literature research, data analysis and statistical analysis; XI: literature search, experimental work, clinical research and data analysis; XYZ: study design, funding acquisition and manuscript review. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Human Ethics Committee of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) and conducted in accordance with the Guidelines of the Declaration of Helsinki. All participants have written to obtain the informed consent of their parents/legal guardians.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pediatrics, Beijing University of Chinese Medicine Shenzhen Hospital (Longgang), No. 1 Dayun Road, Shenzhen City, Guangdong Province 518000, People’s Republic of China. 2Department of Orthopedics, Gansu Provincial Hospital of TCM, Lanzhou City, Gansu Province 730050, People’s Republic of China.

Received: 12 February 2021 Accepted: 22 July 2021
Published online: 06 August 2021

References
1. Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: A systematic review. Lasers Surg Med. 2016;48(3):221–33. https://doi.org/10.1002/lsm.22455.

2. Chen ZY, Wang QN, Zhu YH, Zhou LY, Xu T, He ZY, et al. Progress in the treatment of infantile hemangioma. Annals of translational medicine. 2019;7(22):692. https://doi.org/10.21037/atm.2019.10.47.

3. Léauté-Labrèze C, Harper JL, Hoeger PH. Infantile haemangioma. Lancet (London, England). 2017;390(10089):85–94.

4. Yang L, Dai J, Li F, Cheng H, Yan D, Ruan Q. The expression and function of miR-424 in infantile skin hemangioma and its mechanism. Sci Rep. 2017;7(1):11846. https://doi.org/10.1038/s41598-017-10674-7.

5. Calicchio ML, Collins T, Kozakewich HP. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol. 2009;174(5):1638–49. https://doi.org/10.2353/ajpath.2009.080517.

6. Jathar S, Kumar V, Srivastava J, Tripathi V. Technological Developments in lncRNA Biology. Adv Exp Med Biol. 2017;1008:283–323. https://doi.org/10.1007/978-981-10-5203-3_10.

7. Yang G, Lu X, Yuan L. lncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(1):1097–109. https://doi.org/10.1016/j.bbamg.2014.08.012.

8. Guo C, Qi Y, Qu J, Gai L, Shi Y, Yuan C. Pathophysiological functions of the lncRNA TUG1. Curr Pharm Des. 2020;26(6):688–700. https://doi.org/10.2174/138161282666191227154009.

9. Li T, Chen Y, Zhang J, Liu S. lncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells. Medicine. 2018;97(38):e12131. https://doi.org/10.1097/MD.
0000000000012131.

10. Lei H, Gao Y, Xu X. lncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin. 2017;49(1):588–97. https://doi.org/10.1093/abbs/gmx047.

11. Sheng K, Li Y. lncRNA TUG1 promotes the development of osteosarcoma through RUNX2. Experimental and therapeutic medicine. 2019;18(4):3002–8. https://doi.org/10.3892/etm.2019.8780.

12. Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast cancer (Tokyo, Japan). 2017;24(4):535–43.

13. Sun J, Ding C, Yang Z, Liu T, Zhang X, Zhao C, et al. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J Transl Med. 2016;14(1):42. https://doi.org/10.1186/s12967-016-0786-z.

14. Zhang E, He X, Yin D, Han L, Ouy M, Xu T, et al. Increased expression of long non-coding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis. 2016;7(2):e2109. https://doi.org/10.1038/cddis.2015.356.

15. Lu TX, Rothenberg ME. MicroRNA: A Legacy Clin Immunol. 2018;141(4):1202–7. https://doi.org/10.1007/s10875-017-0354.

16. Li D, Li P, Guo Z, Wang H, Pan W. Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. Int J Mol Med. 2017;39(5):573–63. https://doi.org/10.3892/ijmm.2017.2863.

17. Qi J, Wang WW, Chen W, Lu W, Shang AQ. Mechanism of miR-137 regulating migration and invasion of melanoma cells by targeting PIK3R3 gene. J Cell Biochem. 2018.

18. Li W, Ge J, Xie J, Yang J, Chen J, He T. lncRNA TUG1 Promotes hepatocellular carcinoma migration and invasion via targeting miR-137- AKT2 axis. Cancer Biolther Radiopharm. 2020. https://doi.org/10.1089/cbr.2019.92397.

19. Blumenthal S. From insulin and insulin-like activity to the insulin superfamily of growth-promoting peptides: a 20th-century odyssey. Perspect Biol Med. 2005;48(4):491–508. https://doi.org/10.1353/pbm.2010.0001.

20. Rho SB, Dong SM, Kang S, Seo SS, Yoo CW, Lee DO, et al. Insulin-like growth factor-binding protein-5 acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis. 2008;29(1):233–6. https://doi.org/10.1095/ijc206.

21. Güllü G, Karabulut, S, Akşipiroğlu M. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chinese journal of cancer. 2012;31(6):266–80. https://doi.org/10.3732/jcj.011.10405.

22. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology. 2005;146(7):3113–22. https://doi.org/10.1210/en.2004-1406.

23. Perks CM, McCaig C, Holly JM. Differential insulin-like growth factor (IGF)- independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem. 2000;80(2):248–58. https://doi.org/10.1002/jcb.10022.

24. Hao X, Sun B, Hu L, Lahdesmäki H, Dunnrite F, Feng Y, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004;101(6):1110–22. https://doi.org/10.1002/cncr.20095.

25. Nishidate T, Katagiri T, Lin ML, Mao Y, MiKi Y, Kasumi F, et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser
microbeam microdiessection: identification of genes associated with progression and metastasis. Int J Oncol. 2004;25(4):797–819.

26. Zhang L, Li W, Cao L, Xu J, Qian Y, Chen H, et al. PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53. 2019;38(2):659–664.

27. Zhang T, Guo J, Gu J, Wang Z, Wang G, Li H, et al. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Oncol Rep. 2019;41(1):279–91. https://doi.org/10.3892/or.2018.6840.

28. Chen X, Yu Q, Pan H. Overexpression of IGFBP5 enhances radiosensitivity through PI3K/AKT pathway in prostate cancer. 2020;12:490–8.

29. Dong C, Zhang J, Fang S, Liu F. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells. Cell Div. 2020;15(1):4. https://doi.org/10.1186/s13008-020-00061-6.

30. Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, et al. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget. 2015;6(24):20636–49. https://doi.org/10.18632/oncotarget.4114.

31. Pan J, Li K, Huang W, Zhang X. MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling. PLoS One. 2017;12(10):e0186245. https://doi.org/10.1371/journal.pone.0186245.

32. Khan ZA, Melero-Martin JM, Wu X, Paruchuri S, Boscolo E, Mulliken JB, et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood. 2006;108(3):915–21. https://doi.org/10.1182/blood-2006-03-006478.

33. Dong H, Diao H, Zhao Y, Xu H, Pei S, Gao J. Overexpression of matrix metalloproteinase-9 in breast cancer cell lines remarkably increases the cell malignancy largely via activation of transforming growth factor beta/SMAD signalling. 2019;52(5):e12633.

34. Li MM, Dong CX, Sun B, Lei HZ, Wang YL, Gong YB, et al. LncRNA-MALAT1 promotes tumorigenesis of infantile hemangioma by competitively binding miR-424 to stimulate MEK5/MEK3/NF-kB pathway. Life Sci. 2019;239:116946. https://doi.org/10.1016/j.lfs.2019.116946.

35. Sattendorf KR, Chambers CB. Current treatment and management of infantile hemangiomas. Surv Ophthalmoal. 2019;64(5):608–18. https://doi.org/10.1016/j.survophthal.2019.02.005.

36. Xu MN, Zhang M, Xu Y, Wang M, Yuan SM. Individualized treatment for infantile hemangioma. The Journal of craniofacial surgery. 2018;29(7):1876–9. https://doi.org/10.1097/SCS.0000000000004745.

37. Yu L, Shu H, Xing L, Lv MX, Li L, Xie YC, et al. Silencing long non-coding RNA NEAT1 suppresses the tumorigenesis of infantile hemangioma by competitively binding miR-33a-5p to stimulate HIF1alpha signaling. 2019;52(5):e12634.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.